医疗补助扩大与妇科癌症女性2年生存率:一项双重差分分析
该研究利用美国国家癌症数据库纳入2010至2016年确诊的40至64岁妇科恶性肿瘤女性169731例,采用准实验双重差分多变量Cox回归,比较2014年1月扩大医疗补助州与至2016年未扩大州之间2年生存率。结果显示,扩大州卵巢癌患者2014年后2年生存改善(HR 0.88,95%CI 0.82-0.94,P<.001),其他妇科癌种无差异;扩大州所有癌种未保险比例均更低。
要点
- 扩大州卵巢癌患者2014年后2年生存改善(HR 0.88,95%CI 0.82-0.94,P<.001)。
- 子宫内膜癌、宫颈癌、阴道癌、外阴癌及合并妇科癌种按扩大状态无生存差异。
- 扩大州所有癌种2014年后未保险患者比例均低于未扩大州。
核心结论
- 2014年后扩大医疗补助与卵巢癌女性2年生存改善存在显著关联(HR 0.88,95%CI 0.82-0.94,P<.001)。
- 尽管保险覆盖改善,扩大州与未扩大州之间仍存在种族、民族和地区生存差异。
研究设计与样本
- 研究检索美国国家癌症数据库,纳入2010至2016年确诊原发性妇科恶性肿瘤(子宫内膜、卵巢、宫颈、外阴、阴道)的40至64岁女性。
- 样本共169731例,其中扩大州78669例(46.3%),未扩大州91062例(53.7%)。
- 采用准实验双重差分多变量Cox回归,比较2014年1月扩大医疗补助州与至2016年未扩大州之间的2年生存。
- 按分期、收入、种族、民族和地理区域进行单变量亚组双重差分Cox回归分析。
- 采用调整线性双重差分回归评估2014年后按扩大状态划分的未保险患者比例,并评估调整Kaplan-Meier曲线。
主要发现
- 调整双重差分Cox回归显示,2014年后扩大州卵巢癌女性2年生存优于未扩大州(HR 0.88,95%CI 0.82-0.94,P<.001)。
- 子宫内膜癌、宫颈癌、阴道癌、外阴癌及合并妇科癌种按扩大状态未见生存差异。
- 单变量亚组分析中,扩大州2014年后2年生存改善见于卵巢癌III-IV期(P=.008)、非西班牙裔(P=.042)、南部地区(P=.016)及东北部外阴癌(P=.022)。
- 相反,南部地区宫颈癌女性在扩大州2014年后2年生存更差(P=.018)。
- 2014年后扩大州所有癌种的未保险患者比例均低于未扩大州。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Affordable Care Act implemented optional Medicaid expansion starting in 2014, but the association between Medicaid expansion and gynecologic cancer survival is unknown. OBJECTIVE: To evaluate the impact of Medicaid expansion by comparing 2-year survival among gynecologic cancers before and after 2014 in states that did and did not expand Medicaid using a difference-in-difference analysis. STUDY DESIGN: We searched the National Cancer Database for women aged 40 to 64 years, diagnosed with a primary gynecologic malignancy (endometrial, ovarian, cervical, vulvar, and vaginal) between 2010 and 2016. We used a quasiexperimental difference-in-difference multivariable Cox regression analysis to compare 2-year survival between states that expanded Medicaid in January 2014 and states that did not expand Medicaid as of 2016. We performed univariable subgroup difference-in-difference Cox regression analyses on the basis of stage, income, race, ethnicity, and geographic location. Adjusted linear difference-in-difference regressions evaluated the proportion of uninsured patients on the basis of expansion status after 2014. We evaluated adjusted Kaplan-Meier curves to examine differences on the basis of study period and expansion status. RESULTS: Our sample included 169,731 women, including 78,669 (46.3%) in expansion states and 91,062 (53.7%) in nonexpansion states. There was improved 2-year survival on adjusted difference-in-difference Cox regressions for women with ovarian cancer in expansion than in nonexpansion states after 2014 (hazard ratio, 0.88; 95% confidence interval, 0.82-0.94; P<.001) with no differences in endometrial, cervical, vaginal, vulvar, or combined gynecologic cancer sites on the basis of expansion status. On univariable subgroup difference-in-difference Cox analyses, women with ovarian cancer with stage III-IV disease (P=.008), non-Hispanic ethnicity (P=.042), those in the South (P=.016), and women with vulvar cancer in the Northeast (P=.022), had improved 2-year survival in expansion than in nonexpansion states after 2014. In contrast, women with cervical cancer in the South (P=.018) had worse 2-year survival in expansion than in nonexpansion states after 2014. All cancer sites had lower proportions of uninsured patients in expansion than in nonexpansion states after 2014. CONCLUSION: There was a significant association between Medicaid expansion and improved 2-year survival for women with ovarian cancer in states that expanded Medicaid after 2014. Despite improved insurance coverage, racial, ethnic, and regional survival differences exist between expansion and nonexpansion states.
引用
- Huepenbecker SP, Fu S, Sun CC, et al. Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. 2022. PMID: 35500609. doi:10.1016/j.ajog.2022.04.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。